GSR and cancer: Interestingly, when the 6-position primary amino group of compound 64 was replaced by an anilino group, creating compound 67, a well-known GSR inhibitor LY83583, anti-cancer activity increased approximately 10-fold, while toxicity to hepatocytes was decreased 3-fold.